Literature DB >> 24326352

Glycosylation analysis of an aggregated antibody produced by Chinese hamster ovary cells in bioreactor culture.

Masayoshi Onitsuka1, Akira Kawaguchi2, Ryutaro Asano3, Izumi Kumagai3, Kohsuke Honda2, Hisao Ohtake2, Takeshi Omasa4.   

Abstract

N-Glycosylation of therapeutic antibodies contributes not only to their biological function, but also to their stability and tendency to aggregate. Here, we investigated the impact of the glycosylation status of an aggregated antibody that accumulated during the bioreactor culture of Chinese hamster ovary cells. High-performance liquid chromatography analysis showed that there was no apparent difference in the glycosylation patterns of monomeric, dimeric, and large aggregated forms of the antibody. In contrast, lectin binding assays, which enable the total amounts of specific sugar residues to be detected, showed that both galactose and fucose residues in dimers and large aggregates were reduced to 70-80% of the amount in monomers. These results strongly suggest that the lack of N-linked oligosaccharides, a result of deglycosylation or aglycosylation, occurred in a proportion of the dimeric and large aggregated components. The present study demonstrates that glycosylation heterogeneities are a potential cause of antibody aggregation in cell culture of Chinese hamster ovary cells, and that the lack of N-glycosylation promotes the formation of dimers and finally results in large aggregates.
Copyright © 2013 The Society for Biotechnology, Japan. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody aggregation; Antibody production; Bispecific diabody; Cell culture; Chinese hamster ovary cell; Glycosylation heterogeneity

Mesh:

Substances:

Year:  2013        PMID: 24326352     DOI: 10.1016/j.jbiosc.2013.11.001

Source DB:  PubMed          Journal:  J Biosci Bioeng        ISSN: 1347-4421            Impact factor:   2.894


  5 in total

Review 1.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

2.  Animal Cell Expression Systems.

Authors:  M Butler; U Reichl
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 3.  Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors:  Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

Review 4.  Bispecific antibodies and their applications.

Authors:  Gaowei Fan; Zujian Wang; Mingju Hao; Jinming Li
Journal:  J Hematol Oncol       Date:  2015-12-21       Impact factor: 17.388

Review 5.  Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.

Authors:  Chunpeng Yang; Xinyu Gao; Rui Gong
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.